XenoPort plunges despite positive trial results for psoriasis drug candidate

15 September 2015
xenoport-big

US drug developer XenoPort (Nasdaq: XNPT) had a roller-coaster morning after it announced positive preliminary top-line results from its Phase II clinical trial of XP23829 as a potential treatment for moderate-to-severe chronic plaque-type psoriasis.

In pre-market trading, the stock gained 6.2% to $7.15, but by mid-morning it had plunged 23.4% to $5.16, on investor doubts that XP23829 is differentiated enough from existing psoriasis drugs, including Celgene’s (Nasdaq: CELG) Otezla (apremilast), which gained US regulatory approval a year ago (The Pharma Letter September 24, 2014), and a recent report that an increasing number of rheumatologists view Otezla as a first-line treatment option for psoriatic arthritis before popular anti-TNF treatments such as Humira (adalimumab) from AbbVie (NYSE: ABBV) and Remicade (infliximab) from Janssen, a subsidiary of Johnson & Johnson (NYSE: JNJ; TPL September 9, 2015).

Study details

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical